Genetic counseling referral for ovarian cancer patients: a call to action

Garcia, Christine; Harrison, Kara; Ring, Kari L.; Sullivan, Mackenzie W.; Rauh, Lisa A.; Modesitt, Susan C.

doi:10.1007/s10689-019-00129-5

Cited by 12 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among gynecologic cancers OV has a poor prognosis [1][2][3][4]. Although many target drugs have been applied to OV therapy, the death rate of OV patients is still increasing every year [5][6][7][8]. OV shows resistance to chemotherapy, radiotherapy, and molecularly targeted therapy [9].…”

Section: Introductionmentioning

confidence: 99%

HOXB4 promotes the malignant progression of ovarian cancer via DHDDS

Xiong²,

2020

Preprint

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

HOXB4 promotes the malignant progression of ovarian cancer via DHDDS

Xiong²,

2020

Preprint

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

HOXB4 promotes the malignant progression of ovarian cancer via DHDDS

Gou

Xiong

et al. 2020

Preprint

View full text Add to dashboard Cite

Background : Homeobox B4 (HOXB4) is correlated with poor prognosis of various cancer types. However, how HOXB4 promotes ovarian cancer (OV) progression remains unclear. Methods : The Cancer Genome Atlas (TCGA) database indicated that a high level of HOXB4 in OV was correlated with poor prognosis. The biological functions of HOXB4 were confirmed by colony formation, migration, and invasion assays. The effect of HOXB4 on the expression of EMT cell markers was determined. The transcriptional target of HOXB4 was DHDDS, which was detected by a ChIP assay. A xenograft tumor model was generated in nude mice to detect the role of HOXB4 in tumor proliferation and metastasis. Results : The results showed that HOXB4 protein levels were higher in OV tissues than in normal tissues and correlated with poor prognosis of OV. HOXB4 reduction inhibited the proliferation and invasion ability of OV cells in vitro. Conversely, these effects were enhanced by the upregulation of HOXB4 in OV cells. The binding of HOXB4 to two DNA motifs regulated DHDDS expression and contributed to the malignant progression of OV. The role of HOXB4 in contributing to tumor development in vivo was verified in mice. Further results indicated that HOXB4 induced Snail and Zeb1 expression. Conclusion : Overall, HOXB4 overexpression was remarkably correlated with poor prognosis of OV. Mechanistically, HOXB4 enhances the proliferation and invasion of tumor cells by activating DHDDS, thereby promoting the malignant progression of OV.

show abstract

“…[14][15][16][17] It is currently unknown how often children with a suspected CPS are referred for further evaluation but rates of genetic referral uptake for adult oncology range from 22-68%. [18][19][20][21][22] If rates are similar for the pediatric population, there may be a significant number of CPS cases undiagnosed due to low referral uptake, however, if referral does not occur, uptake is irrelevant. Numerous barriers to genetics referrals have been identified in other specialties but data in the pediatric oncology setting are sparse.…”

Section: Introductionmentioning

confidence: 99%

“…Numerous barriers to genetics referrals have been identified in other specialties but data in the pediatric oncology setting are sparse. 19,[23][24][25][26][27][28][29][30][31][32] The specific aims of this study were to: i.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of barriers to referral for cancer predisposition syndromes in pediatric oncology patients

Venier

Grubs

Kessler

et al. 2020

Preprint

View full text Add to dashboard Cite

Genomic medicine and the use of genetic information in pediatric oncology has provided insight on the molecular underpinnings of childhood cancers and has demonstrated that cancer predisposition syndromes (CPS) are underdiagnosed. Diagnosis of a CPS has important implications for the patient and their family. In childhood, CPS are often diagnosed by geneticists or oncologists with expertise in CPS following a malignancy, however, this requires a member of the care team, most commonly, the treating oncologist to suspect a CPS and refer them for assessment. We sought to understand current referral practices of pediatric oncology healthcare providers and barriers to referral for evaluation of a CPS. An online survey was sent to members of the Children's Oncology Group. Of the 189 respondents, 80.4% were pediatric hematologists/oncologists and most (69%) used formal guidelines to aid in referral assessment.Guideline use was associated with a higher proportion (>5%) of patients with a CPS in the respondent's practice. Participants were more likely to refer patients with malignancy and additional features of a CPS than for a specific type of cancer, despite the use of guidelines. Most respondents indicated they would rarely refer patients with tumors highly associated with CPS.Patient/parent knowledge of family history was considered the most challenging barrier to obtaining a family history, though a thorough three-generation pedigree was not consistently attempted. Overall, participants indicated the most significant barrier to referral was priority given the patient's more immediate care needs. Other barriers to genetics referral identified elsewhere

show abstract

Genetic counseling referral for ovarian cancer patients: a call to action

Cited by 12 publications

References 19 publications

HOXB4 promotes the malignant progression of ovarian cancer via DHDDS

HOXB4 promotes the malignant progression of ovarian cancer via DHDDS

HOXB4 promotes the malignant progression of ovarian cancer via DHDDS

Evaluation of barriers to referral for cancer predisposition syndromes in pediatric oncology patients

Contact Info

Product

Resources

About